A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients Estudio fase II, randomizado, doble ciego, controlado con placebo, de escalonamiento de dosis para evaluar la seguridad y los efectos de Conivaptan intravenoso sobre la respuesta hemodinámica hepática en pacientes cirróticos euvolémicos o hipervolémicos estables The objectives of this study are to evaluate the safety of two different doses of IV conivaptan (YM087 or Vaprisol®) in stable euvolemic or hypervolemic cirrhotic patients with serum sodium 115 – 140 ...

• Country None
• organs None
• Specialty None

A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) The primary objective of this study is to evaluate the urodynamic variables of male subjects with LUTS and BOO treated with the co-administration of 6 mg solifenacin succinate and TOCAS, and 9 mg soli...

• Country None
• organs None
• Specialty None

A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation To evaluate the safety of RSD1235 in subjects with atrial fibrillation (AF).

• Country None
• organs None
• Specialty None

A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of AF or AFL to SR. Treatment will be considered successful if there is a treatment-induced conversion of atrial arrhyt...

• Country None
• organs None
• Specialty None

A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects To evaluate the overall response rate (Complete Remission + Partial Remission) of YM155 per the International Working Group Criteria (IWG, 2007) during 15 cycles of treatment.

• Country None
• organs None
• Specialty None